Oncotelic Therapeutics, Inc. (OTLC): Operating Income
-$3.19M
Year ended 2025-12-31
-$5.72M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$3.19M | n/m | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | -$3.58M | n/m | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | -$6.65M | n/m | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | -$9.72M | n/m | 2024-04-12, From 2022-01-01 |
| 2021-12-31 | -$9.13M | n/m | 2023-04-20, From 2021-01-01 |
| 2020-12-31 | -$7.58M | n/m | 2022-04-15, From 2020-01-01 |
| 2019-12-31 | -$4.31M | n/m | 2021-04-15, From 2019-01-01 |
| 2018-12-31 | -$712.7K | n/m | 2020-05-14, From 2018-01-01 |
| 2017-12-31 | -$13.84M | n/m | 2019-04-10, From 2017-01-01 |
| 2016-12-31 | -$13.76M | n/m | 2018-04-17, From 2016-01-01 |
| 2015-12-31 | -$13.68M | n/m | 2017-03-30, From 2015-01-01 |
| 2014-12-31 | -$12.65M | n/m | 2016-03-25, From 2014-01-01 |
| 2013-12-31 | -$8.28M | n/m | 2015-03-30, From 2013-01-01 |
| 2012-12-31 | -$8.07M | n/m | 2015-03-30, From 2012-01-01 |
| 2011-12-31 | -$11.89M | n/m | 2014-03-20, From 2011-01-01 |
| 2010-12-31 | -$18.51M | n/m | 2013-03-15, From 2010-01-01 |
| 2009-12-31 | -$31.16M | n/a | 2012-03-28, From 2009-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Oncotelic Therapeutics, Inc. (OTLC) | 2025-12-31 | -$3.19M | n/m |
| Erasca, Inc. (ERAS) | 2025-12-31 | -$140.91M | n/m |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $98.50M | +5.8% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | -$111.29M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | $30.52M | +245.9% |
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | -$98.06M | n/m |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | -$383.06M | n/m |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $24.90M | n/m |
| Nkarta, Inc. (NKTX) | 2025-12-31 | -$122.00M | n/m |
Compare OTLC, ERAS, IRWD, TNGX side by side · Screen every company in Pharmaceutical Preparations ↗